BridgeBio Pharma (BBIO) Competitors $54.47 -0.83 (-1.51%) As of 11:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BBIO vs. ONC, INSM, BNTX, TEVA, GMAB, SMMT, ASND, VTRS, RDY, and MRNAShould you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. BridgeBio Pharma vs. Its Competitors BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna BeOne Medicines (NASDAQ:ONC) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Is ONC or BBIO more profitable? BeOne Medicines has a net margin of -3.89% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BeOne Medicines-3.89% -1.22% -0.72% BridgeBio Pharma -329.25%N/A -85.69% Which has more risk and volatility, ONC or BBIO? BeOne Medicines has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Do analysts recommend ONC or BBIO? BeOne Medicines presently has a consensus target price of $340.30, indicating a potential upside of 0.99%. BridgeBio Pharma has a consensus target price of $63.94, indicating a potential upside of 17.40%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90BridgeBio Pharma 1 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has preferable earnings and valuation, ONC or BBIO? BridgeBio Pharma has lower revenue, but higher earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeOne Medicines$3.81B9.69-$644.79M-$1.73-194.79BridgeBio Pharma$221.90M46.92-$535.76M-$4.09-13.32 Does the media favor ONC or BBIO? In the previous week, BeOne Medicines had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 8 mentions for BeOne Medicines and 7 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.92 beat BeOne Medicines' score of 0.61 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in ONC or BBIO? 48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by company insiders. Comparatively, 18.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryBridgeBio Pharma beats BeOne Medicines on 10 of the 17 factors compared between the two stocks. Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBIO vs. The Competition Export to ExcelMetricBridgeBio PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.44B$4.52B$9.08B$10.58BDividend YieldN/A0.90%5.69%4.71%P/E Ratio-13.3511.0786.1627.45Price / Sales46.9222.58539.92202.26Price / CashN/A7.0637.9261.55Price / Book-7.064.3513.056.77Net Income-$535.76M-$134.23M$3.30B$275.88M7 Day Performance2.23%6.67%4.55%2.63%1 Month Performance1.81%13.02%9.73%9.10%1 Year Performance132.96%74.05%85.10%35.69% BridgeBio Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBIOBridgeBio Pharma4.2261 of 5 stars$54.47-1.5%$63.94+17.4%+123.6%$10.44B$221.90M-13.35400Analyst ForecastONCBeOne Medicines1.478 of 5 stars$344.53+0.2%$336.30-2.4%N/A$37.69B$3.81B-199.1511,000Analyst ForecastGap DownINSMInsmed3.271 of 5 stars$158.28+0.7%$149.06-5.8%+126.7%$33.22B$363.71M-27.721,271Analyst ForecastBNTXBioNTech2.6579 of 5 stars$105.16-0.3%$134.56+28.0%-11.7%$25.36B$2.98B-65.726,772Positive NewsTEVATeva Pharmaceutical Industries3.1669 of 5 stars$19.99-0.1%$25.57+27.9%+15.3%$22.95B$16.54B-124.9436,830Analyst ForecastAnalyst RevisionGMABGenmab A/S4.3488 of 5 stars$33.31-0.7%$40.80+22.5%+38.8%$21.55B$3.12B16.742,682Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics3.1711 of 5 stars$22.15+3.4%$31.29+41.2%+18.5%$15.92B$700K-21.93110Analyst ForecastASNDAscendis Pharma A/S3.0462 of 5 stars$210.83+3.3%$244.36+15.9%+59.1%$12.59B$393.54M-40.861,017News CoverageAnalyst ForecastHigh Trading VolumeVTRSViatris1.685 of 5 stars$10.13-0.6%$10.40+2.7%-11.9%$11.88B$14.74B-3.4932,000Analyst ForecastRDYDr. Reddy's Laboratories3.2588 of 5 stars$14.12-0.3%$16.95+20.0%-11.1%$11.82B$3.81B21.3927,811News CoveragePositive NewsAnalyst ForecastMRNAModerna4.3205 of 5 stars$27.54-3.3%$41.81+51.8%-52.2%$11.08B$3.24B-3.665,800Analyst Forecast Related Companies and Tools Related Companies BeOne Medicines Alternatives Insmed Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives Moderna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BBIO) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
